MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease

doi:10.4239/wjd.v15.i7.1398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (423)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

221

Figures (1-1)

Sum=326

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=59

Jul 15, 2024 (publication date) through Jul 31, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Jul 15, 2024; 15(7): 1398-1403
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1398

MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease

Javier Donate-Correa, Ainhoa González-Luis, Jésica Díaz-Vera, Juan Ramón Hernandez-Fernaud

Javier Donate-Correa, Ainhoa González-Luis, Jésica Díaz-Vera, Research Unit, University Hospital Nuestra Señora de Candelaria (UHNSC), Santa Cruz de Tenerife 38010, Spain

Juan Ramón Hernandez-Fernaud, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Santa Cruz de Tenerife 38000, Spain

Author contributions: Donate-Correa J, González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR designed this editorial; González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR contributed to the data collection and editing of the manuscript; Donate-Correa J wrote the paper; All the authors have read and approved the final version of the present manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Javier Donate-Correa, PhD, Research Scientist, Teacher, Research Unit, University Hospital Nuestra Señora de Candelaria (UHNSC), Carretera del Rosario S/N, Santa Cruz de Tenerife 38010, Spain. jdonatecorrea@gmail.com

Received: February 10, 2024
Revised: March 18, 2024
Accepted: April 22, 2024
Published online: July 15, 2024
Processing time: 148 Days and 15.3 Hours

Core Tip

Core Tip: Targeting Toll-like receptors (TLRs) via microRNAs is a promising therapeutic approach for reducing inflammation and slowing the progression of diabetic kidney disease (DKD). Understanding how TLR4 expression and signaling are linked to microRNAs regulation, may pave the path for future targeted clinical interventions in DKD.